0.806

2.35% 0.0185

Rein Therapeutics Inc (RNTX)

Overview News Price History Discussions Forecast

Rein Therapeutics Inc stock is traded at $0.806, with a volume of 210.92K. It is up +2.35% in the last 24 hours and down -11.99% over the past month. Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Previous Close:

$0.7875

Open:

$0.81

24h Volume:

210.92K

Relative Volume:

0.43

Market Cap:

$68.94M

Revenue:

Net Income/Loss:

$-50.21M

P/E Ratio:

-0.423

EPS:

-1.9053

Net Cash Flow:

$-16.61M

1W Performance:

-1.41%

1M Performance:

-11.99%

6M Performance:

-28.04%

1Y Performance:

-30.22%

1-Day Range:

$0.7601

$0.8171

1-Week Range:

$0.7593

$0.855

52-Week Range:

$0.694

$2.18

Rein Therapeutics Inc Stock (RNTX) Company Profile

Name

Rein Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(737) 802-1989

Address

12407 N. MOPAC EXPY., AUSTIN

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

RNTX's Discussions on Twitter

Compare RNTX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNTX Rein Therapeutics Inc	0.806	68.86M	0	-50.21M	-16.61M	-1.9053
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-25	Initiated	H.C. Wainwright	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-24-17	Initiated	BofA/Merrill	Buy
Jul-24-17	Initiated	Jefferies	Buy
Jul-24-17	Initiated	William Blair	Outperform

Rein Therapeutics Inc Stock (RNTX) Latest News

Aug 14, 2026

Rein Therapeutics (NASDAQ:RNTX) Announces Earnings Results - MarketBeat

Aug 14, 2026

Rein Therapeutics Raises $44.3 Million in Public Offering - Minichart

Aug 14, 2026

Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

Aug 14, 2026

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Aug 14, 2026

Rein Therapeutics Surpasses 25% Enrollment in Phase 2 RENEW Trial of LTI-03 for IPF, Completes $57.5 Million Public Offering - quiverquant.com

Aug 14, 2026

Rein Therapeutics 2Q 2026: Revenue $0 Net loss $6.4M, EPS $(0.10) — 10-Q Summary - TradingView

Aug 14, 2026

RNTX: Q2 net loss narrowed, liquidity strengthened, and Phase 2 LTI-03 trial remains on track - TradingView

Aug 14, 2026

Rein Therapeutics Inc. (NASDAQ:RNTX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

Aug 14, 2026

Aug 11, 2026

Rein Therapeutics (NASDAQ:RNTX) Shares Down 2.9%Here's Why - MarketBeat

Aug 11, 2026

Aug 10, 2026

Rein Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Aug 10, 2026